PrIMAVeRa 1st annual meeting successfully held in a hybrid event in Verona on 29-30 November 2022
‘PrIMAVeRa’ means ‘Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance’.
It is a European project funded by the Innovative Medicines Initiative 2 (IMI2) with the goal of developing an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding the prioritisation of specific vaccines and monoclonal antibodies (mAbs), informing the strategic allocation of limited resources.
A project sustainability plan will also be designed by the project partners with the goal of providing long-term access to the project results, including the models, once the project has finished.
PRIMAVERA is part of the AMR Accelerator Programme.

At a glance
Innovations to accelerate vaccine development and manufacture
TIMELINE
01.11.2021-30.11.2026
(5 Years)
COORDINATOR
European Vaccine Initiative (EVI)
FUNDER
Innovative Medicines Initiative 2 (IMI2) and European Federation of Pharmaceutical Industries and Associations (EFPIA)
FUNDING
€9.25 Mio
(€6.5 Mio from IMI2 and €2.75 Mio from EFPIA)
![]() Scientist on Computer_edited_edited |
---|
![]() Conference |
![]() Add a Title |
![]() icon_PrIMAVeRA_crop |
![]() Laboratory |
![]() Drug and Syringe |
![]() Girl at the Pediatrician |
![]() Pipetting Samples |
![]() hand shake_Inno4Vac KoM_Source Wix |
![]() Add a Title |
![]() Preventive services |
![]() Add a Title |